Indegene Share Price Rises 3% as Major Investors Acquire Stake

Market Performance

Indegene's share price surged 3% on Thursday, recovering from the previous day's losses. The stock reached an intraday high of ₹609.80, which is still 20% below its 52-week peak of ₹736.30.

This rebound followed a 4% drop on Wednesday after Carlyle Group sold its entire 10.2% stake in the company.

Key Stakeholders' Transactions

Several prominent investors acquired shares in bulk, boosting market sentiment:

• PI Opportunities (Azim Premji-backed) invested ₹100 Crore
• Societe Generale (France) bought a 0.21% stake for ₹111 Crore
• Capital Group's Small Cap World Fund pumped in ₹108 Crore
• Eastbridge Capital acquired a 0.24% stake for ₹128 Crore

Collectively, these investors picked up 1.06 Crore shares (4.42% stake) for ₹627 Crore at ₹591–591.48 per share.

Carlyle Group's Exit Strategy

Carlyle Group, which initially invested ₹917 Crore in 2021 at ₹201 per share, exited in phases:

• IPO (May 2024): Sold shares at ₹452
• December 2024: Offloaded stake at ₹618
• June 2025: Final exit at ₹591 per share

The private equity firm secured strong returns across different market conditions.

Company Overview

Indegene, a global healthcare solutions provider, went public in May 2024. Its expansion and IPO attracted significant investor interest before Carlyle's exit.

Summary

• Indegene's share price rose 3% after major investors bought stakes.
• ₹627 Crore worth of shares exchanged hands in block deals.
• Carlyle Group exited completely, booking profits after a 4-year investment.

The stock remains 20% below its 52-week high.